| Jonathan Edward Lee, DO | |
|
1 Hospital Dr Bldg Dc032.00, Columbia, MO 65212-1000 | |
| (573) 882-2100 | |
| (573) 884-6109 |
| Full Name | Jonathan Edward Lee |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 6 Years |
| Location | 1 Hospital Dr Bldg Dc032.00, Columbia, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033606587 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Minnesota Medical Center, Fairview | Minneapolis, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Fairview Health Services | 1951213057 | 559 |
News Archive
In the tiny House Rules Committee room in Congress on Wednesday, New York Democrat Louise Slaughter let roll her grievances against House Republicans' lawsuit against Barack Obama. It took a lot of coffee.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
High risk, frail heart patients might derive benefits from "prehabilitation," a strategy designed to enhance the recovery process after heart surgery by maintaining or improving the patient's overall physical and mental status before surgery, according to a group of eminent cardiac specialists writing in the Canadian Journal of Cardiology.
WomanCare Global is pleased to announce an expansion of their global product portfolio to include Roselle, a combined oral contraceptive (COC) pill containing 150 micrograms of levonorgestrel and 30 micrograms of ethinylestradiol and Optinor, a progesterone-only emergency contraception pill (ECP) containing 750 micrograms of levonorgestrel.
› Verified 6 days ago
| Entity Name | University Of Minnesota Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477598118 PECOS PAC ID: 9830001189 Enrollment ID: O20031104000532 |
News Archive
In the tiny House Rules Committee room in Congress on Wednesday, New York Democrat Louise Slaughter let roll her grievances against House Republicans' lawsuit against Barack Obama. It took a lot of coffee.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
High risk, frail heart patients might derive benefits from "prehabilitation," a strategy designed to enhance the recovery process after heart surgery by maintaining or improving the patient's overall physical and mental status before surgery, according to a group of eminent cardiac specialists writing in the Canadian Journal of Cardiology.
WomanCare Global is pleased to announce an expansion of their global product portfolio to include Roselle, a combined oral contraceptive (COC) pill containing 150 micrograms of levonorgestrel and 30 micrograms of ethinylestradiol and Optinor, a progesterone-only emergency contraception pill (ECP) containing 750 micrograms of levonorgestrel.
› Verified 6 days ago
| Entity Name | Fairview Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013994359 PECOS PAC ID: 1951213057 Enrollment ID: O20031105000461 |
News Archive
In the tiny House Rules Committee room in Congress on Wednesday, New York Democrat Louise Slaughter let roll her grievances against House Republicans' lawsuit against Barack Obama. It took a lot of coffee.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
High risk, frail heart patients might derive benefits from "prehabilitation," a strategy designed to enhance the recovery process after heart surgery by maintaining or improving the patient's overall physical and mental status before surgery, according to a group of eminent cardiac specialists writing in the Canadian Journal of Cardiology.
WomanCare Global is pleased to announce an expansion of their global product portfolio to include Roselle, a combined oral contraceptive (COC) pill containing 150 micrograms of levonorgestrel and 30 micrograms of ethinylestradiol and Optinor, a progesterone-only emergency contraception pill (ECP) containing 750 micrograms of levonorgestrel.
› Verified 6 days ago
| Entity Name | Fairview Clinics |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346432218 PECOS PAC ID: 7113830142 Enrollment ID: O20031106000516 |
News Archive
In the tiny House Rules Committee room in Congress on Wednesday, New York Democrat Louise Slaughter let roll her grievances against House Republicans' lawsuit against Barack Obama. It took a lot of coffee.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
High risk, frail heart patients might derive benefits from "prehabilitation," a strategy designed to enhance the recovery process after heart surgery by maintaining or improving the patient's overall physical and mental status before surgery, according to a group of eminent cardiac specialists writing in the Canadian Journal of Cardiology.
WomanCare Global is pleased to announce an expansion of their global product portfolio to include Roselle, a combined oral contraceptive (COC) pill containing 150 micrograms of levonorgestrel and 30 micrograms of ethinylestradiol and Optinor, a progesterone-only emergency contraception pill (ECP) containing 750 micrograms of levonorgestrel.
› Verified 6 days ago
| Entity Name | Healtheast Medical Research Institute |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639125503 PECOS PAC ID: 3971407636 Enrollment ID: O20031124000507 |
News Archive
In the tiny House Rules Committee room in Congress on Wednesday, New York Democrat Louise Slaughter let roll her grievances against House Republicans' lawsuit against Barack Obama. It took a lot of coffee.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
High risk, frail heart patients might derive benefits from "prehabilitation," a strategy designed to enhance the recovery process after heart surgery by maintaining or improving the patient's overall physical and mental status before surgery, according to a group of eminent cardiac specialists writing in the Canadian Journal of Cardiology.
WomanCare Global is pleased to announce an expansion of their global product portfolio to include Roselle, a combined oral contraceptive (COC) pill containing 150 micrograms of levonorgestrel and 30 micrograms of ethinylestradiol and Optinor, a progesterone-only emergency contraception pill (ECP) containing 750 micrograms of levonorgestrel.
› Verified 6 days ago
| Entity Name | Fairview Express Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053952606 PECOS PAC ID: 3375645179 Enrollment ID: O20081028000548 |
News Archive
In the tiny House Rules Committee room in Congress on Wednesday, New York Democrat Louise Slaughter let roll her grievances against House Republicans' lawsuit against Barack Obama. It took a lot of coffee.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
High risk, frail heart patients might derive benefits from "prehabilitation," a strategy designed to enhance the recovery process after heart surgery by maintaining or improving the patient's overall physical and mental status before surgery, according to a group of eminent cardiac specialists writing in the Canadian Journal of Cardiology.
WomanCare Global is pleased to announce an expansion of their global product portfolio to include Roselle, a combined oral contraceptive (COC) pill containing 150 micrograms of levonorgestrel and 30 micrograms of ethinylestradiol and Optinor, a progesterone-only emergency contraception pill (ECP) containing 750 micrograms of levonorgestrel.
› Verified 6 days ago
| Entity Name | University Of Minnesota Health Clinics And Surgery Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053795187 PECOS PAC ID: 9133423304 Enrollment ID: O20160209000524 |
News Archive
In the tiny House Rules Committee room in Congress on Wednesday, New York Democrat Louise Slaughter let roll her grievances against House Republicans' lawsuit against Barack Obama. It took a lot of coffee.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
High risk, frail heart patients might derive benefits from "prehabilitation," a strategy designed to enhance the recovery process after heart surgery by maintaining or improving the patient's overall physical and mental status before surgery, according to a group of eminent cardiac specialists writing in the Canadian Journal of Cardiology.
WomanCare Global is pleased to announce an expansion of their global product portfolio to include Roselle, a combined oral contraceptive (COC) pill containing 150 micrograms of levonorgestrel and 30 micrograms of ethinylestradiol and Optinor, a progesterone-only emergency contraception pill (ECP) containing 750 micrograms of levonorgestrel.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jonathan Edward Lee, DO 1 Hospital Dr Bldg Dc032.00, Columbia, MO 65212-1000 Ph: (573) 882-2100 | Jonathan Edward Lee, DO 1 Hospital Dr Bldg Dc032.00, Columbia, MO 65212-1000 Ph: (573) 882-2100 |
News Archive
In the tiny House Rules Committee room in Congress on Wednesday, New York Democrat Louise Slaughter let roll her grievances against House Republicans' lawsuit against Barack Obama. It took a lot of coffee.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
High risk, frail heart patients might derive benefits from "prehabilitation," a strategy designed to enhance the recovery process after heart surgery by maintaining or improving the patient's overall physical and mental status before surgery, according to a group of eminent cardiac specialists writing in the Canadian Journal of Cardiology.
WomanCare Global is pleased to announce an expansion of their global product portfolio to include Roselle, a combined oral contraceptive (COC) pill containing 150 micrograms of levonorgestrel and 30 micrograms of ethinylestradiol and Optinor, a progesterone-only emergency contraception pill (ECP) containing 750 micrograms of levonorgestrel.
› Verified 6 days ago
Dr. Rahul Jain, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Hospital Dr, Columbia, MO 65212 Phone: 573-884-2296 Fax: 573-884-7743 | |
Gregory Gaskey, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1 Hospital Dr, Columbia, MO 65212 Phone: 573-884-9066 Fax: 573-884-3037 | |
Christos N Papageorgiou, M.D., PHD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: One Hospital Drive, Columbia, MO 65212 Phone: 573-882-2100 Fax: 573-884-7822 | |
Jack Bragg, DO Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 101 S Fairview Road, Columbia, MO 65201 Phone: 573-884-7600 Fax: 573-884-8200 | |
Michelle Middleton Woodson, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 800 Hospital Dr, Columbia, MO 65201 Phone: 573-814-6000 Fax: 573-814-6584 | |
Dr. Sameer Bellapravalu, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Hospital Drive Room 313, Psychiatry Dept Dc067.00, Columbia, MO 65212 Phone: 573-884-6136 Fax: 573-884-1070 | |
Trenton Bickel, Internal Medicine Medicare: Medicare Enrolled Practice Location: 1 Hospital Dr # Dc043.00, Columbia, MO 65212 Phone: 573-882-7272 |